Final

Data Collection on the Toxicity, Use, and 

Disposal of Hazardous Drugs Report

Prepared for:

U.S. Environmental Protection Agency

Materials Recovery and Waste Management Division

Office of Resource Conservation and Recovery

1200 Pennsylvania Avenue, NW

Washington, D.C. 20460

Prepared by:

Eastern Research Group, Inc.

14555 Avion Parkway

Suite 200

Chantilly, VA 20151-1102

September 2011

EPA Contract No. EP-W-10-055

Task Order SOL-HQ-11-00035
i

Contents

Page

Contents............................................................................................................................... i

List of Tables ......................................................................................................................ii

Executive Summary............................................................................................................ v

1. INTRODUCTION TO THE HAZARDOUS DRUG DATA COLLECTION.......................................1-1

2. RESOURCE CONSERVATION AND RECOVERY ACT REGULATIONS FOR U AND P

LISTED WASTES................................................................................................................2-1

3. IDENTIFICATION OF HAZARDOUS DRUGS AND REVIEW OF TOXICITY DATA .....................3-1

3.1 NIOSH List of Hazardous Drugs.........................................................................3-1

3.2 OSHA List of Hazardous Drugs..........................................................................3-2

3.3 Proposed Additions and Deletions to the NIOSH Hazardous Drug List .............3-3

3.4 Collection of Toxicity Data .................................................................................3-3

3.4.1 Data Sources ............................................................................................3-3

3.4.2 Data Collection Approach........................................................................3-6

3.4.3 Design of Hazardous Drugs Toxicity Data Spreadsheet..........................3-6

3.5 Review of Lethal Toxicity Data...........................................................................3-6

4. EXTENT OF DRUG USE AND CURRENT DISPOSAL PRACTICES ...........................................4-1

4.1 Extent of Drug Use ..............................................................................................4-1

4.2 Current Drug Disposal Practices..........................................................................4-3

4.2.1 Regulations Affecting Drug Disposal Practices ......................................4-5

4.2.2 Federal Drug Administration’s Recommendations for Flushing 

Unused Drugs...........................................................................................4-6

5. REFERENCES .....................................................................................................................5-1

Appendix A: LIST OF HAZARDOUS DRUGS REVIEWED BY ERG

Appendix B: TOXICITY DATA

Appendix C: LIST OF CONTROLLED SUBSTANCES BY DEA SCHEDULE
ii

List of Tables

Page

3-1 Sources of Formulary Information................................................................................... 3-4

3-2 Sources of Lethal Dose Data............................................................................................ 3-4

3-3 Sources of Toxicity Information...................................................................................... 3-4

4-1 Commonly Prescribed Drugs in 2005 and 2009 .............................................................. 4-2

4-2 U.S. Production Ranges for Appendix A Drugs.............................................................. 4-3

4-3 Current Drug Disposal Practices at Healthcare Facilities................................................ 4-4

4-4 Drugs Recommended for Disposal By Flushing ............................................................. 4-6

A-1 List of Drugs Reviewed by ERG and Tier Assignments.....................................................1

C-1 Schedule I Controlled Substances........................................................................................1

C-2 Schedule II Controlled Substances ......................................................................................4

C-3 Schedule III Controlled Substances.....................................................................................6

C-4 Schedule IV Controlled Substances...................................................................................10

C-5 Schedule V Controlled Substances....................................................................................12
iii

ACRONYM LIST

ACGIH: American Conference of Government Industrial Hygienists

AHFS DI: American Hospital Formulary Service Drug Information

ASHP: American Society of Health-System Pharmacists

BEI: Biological Exposure Indices

CASRN: Chemical Abstracts Service Registry Number

CCL3: Contaminant Candidate List 3

CFR: Code of Federal Regulations

CPDB: Carcinogenic Potency Database

CSA: Controlled Substances Act

CSF: Cancer Slope Factor

CUS/IUR: Chemical Update System/Inventory Update Rule

DEA: Drug Enforcement Administration

DSSTox: Distributed Structure-Searchable Toxicity

DWEL: Drinking Water Equivalent Level

EPA: U.S. Environmental Protection Agency

ERG: Eastern Research Group, Inc.

FDA: U.S. Food and Drug Administration

FR: Federal Register

HA: Health Advisories

HSDB: Hazardous Substances Data Bank

IARC: International Agency for Research on Cancer

IDLH: Immediately Dangerous to Life or Health Concentration

IRIS: Integrated Risk Information System

IUR: Inhalation Unit Risk

IV: Intravenous

LC: Lethal Concentration

LD: Lethal Dose

LDL: Lowest Dose Causing Lethality

LTHA: Lifetime Health Advisory

MCL: Maximum Contaminant Level

mg/kg: Milligrams per Kilogram

mg/L: Milligrams per Liter

MRDD: Maximum Recommended Daily Dose

MRTD: Maximum Recommended Therapeutic Dose

NCEA: National Center for Environmental Assessment

NIH: National Institutes of Health

NIOSH: National Institute for Occupational Safety and Health 

NLM: National Library of Medicine

NTP: National Toxicology Program

OEHHA: Office of Environmental Health Hazard Assessment

ORCR: Office of Resource Conservation and Recovery

OSHA: Occupational Safety and Health Administration

OW: Office of Water

PEL: Permissible Exposure Limit

PhRMA: Pharmaceutical Research and Manufacturers of America

RCRA: Resource Conservation and Recovery Act
iv

REL: Recommended Exposure Limit

RoC: Report on Carcinogens

RfC: Reference Concentration

RfD: Reference Dose

RTECS: Registry of Toxic Effects of Chemical Substances

TLV: Threshold Limit Value
v

EXECUTIVE SUMMARY

With the advent of new chemotherapy (antineoplastic) drugs, as well as the development of a 

variety of new drugs that exhibit hazardous properties, it has become important for the U.S. 

Environmental Protection Agency’s (EPA’s) Office of Resource Conservation and Recovery 

(ORCR) to conduct additional research to update U and P coded hazardous wastes to address 

those drugs that present an acute toxicity risk or could cause serious irreversible illness if 

disposed of improperly. The disposal of hazardous drugs impacts both land and water, as 

improperly-disposed drugs can end up in the municipal waste landfills and waters of the United 

States. Eastern Research Group, Inc. (ERG) is supporting EPA in its collection and analysis of 

toxicity, use, and disposal data for drugs that exhibit hazardous properties under Task Order 

SOL-HQ-11-00035. 

ERG collected toxicity, extent of use, and disposal data for 204 drugs: 172 drugs identified as 

hazardous by the National Institute for Occupational Safety and Health (NIOSH) and the 

Occupational Safety and Health Administration (OSHA) and 32 drugs that NIOSH proposed for 

addition to its hazardous drug list. ERG then created a Microsoft ExcelTM spreadsheet to capture 

the toxicity data for those drugs and analyzed the lethality data to determine the appropriate tier 

category for each drug (see Section 3.4). Based on the lethal dose data analysis, ERG found that 

11 drugs on the NIOSH or OSHA lists of hazardous drugs meet the specific criteria set forth in

Code of Federal Regulations (CFR) §261.11 for acute toxicity. Three of these drugs are already 

included on the federal Resource Conservation and Recovery Act (RCRA) list of hazardous 

chemicals (U list).

 Carmustine (154-93-8)

 Cisplatin (15663-27-1)

 Colchicine (64-86-8)

 Dactinomycin (50-76-0)

 Mechlorethamine (51-75-2)

 Melphalan (148-82-3) – EPA 

Waste Code U150

 Mitomycin (50-07-7) – EPA Waste 

Code U010

 Mitoxantrone HCl (70476-82-3)

 Oxytocin (50-56-6)

 Thiotepa (52-24-4)

 Uracil mustard (66-75-1) – EPA 

Waste Code U237

An additional 114 drugs1on the NIOSH or OSHA lists did not meet the specific criteria in 

§261.11 for acute toxicity, but did have lethal doses for other animals or humans.

ERG also reviewed available public literature to determine whether the 204 drugs are commonly 

prescribed in the United States. Based on data for 2009, 12 antineoplastic agents (chemotherapy

drugs) and eight other classification drugs were among the top 200 prescribed. ERG did not 

identify any available data to determine quantities of drug waste disposed by healthcare facilities.

 

1 Two of the 114 drugs (Docetaxel and Mycophenolic acid) were categorized as Tier 2 drugs based on one of the 

Chemical Abstracts Service Registry Numbers (CASRNs); the drugs fall into the Tier 3 category based on the other 

CASRN. Seventeen of the 114 Tier 2 drugs have very little lethality data (borderline Tier 3). One of the 114 Tier 2 

drugs almost meets the Tier 1 criteria (Podofilox [518-28-5]).
1-1

1. INTRODUCTION TO THE HAZARDOUS DRUG DATA COLLECTION 

On December 2, 2008, EPA proposed adding hazardous pharmaceutical (drug) wastes to the 

Federal universal waste program (73 Federal Register [FR] 73520) to provide a hazardous 

pharmaceutical waste disposal system that is protective of public health and the environment. 

Through the public comments on the proposal and via outside communications, stakeholders 

asserted that numerous drugs are harmful to human health and the environment when improperly 

disposed; however, these drugs have not yet been recognized as hazardous waste by EPA.

Drug waste includes discarded drugs and associated equipment generated by hospitals and other 

facilities that use such drugs. A number of drugs are included on the U and P coded hazardous 

waste lists as commercial chemical products. However, EPA created these lists more than 30 

years ago and there are now many newer chemotherapy and other toxic drugs that should be 

assessed for potential listing as U or P wastes. This document summarizes data and other 

information collected for 204 drugs identified as hazardous or potentially hazardous by NIOSH 

and OSHA. Within this document, Section 2 presents a brief overview of the toxicity 

requirements for chemicals listed on the U and P coded hazardous waste lists; Section 3 

describes how ERG collected and analyzed the data to categorize each drug into a tier; and 

Section 4 describes the extent of use for the drugs reviewed and provides an overview of current 

healthcare industry disposal practices.
2-1

2. RESOURCE CONSERVATION AND RECOVERY ACT REGULATIONS FOR U AND P LISTED 

WASTES

Under the Resource Conservation and Recovery Act (RCRA), EPA may classify a chemical as 

hazardous if the chemical is specifically listed in the regulations or exhibits certain 

characteristics. Thus, a drug waste may be considered hazardous under RCRA if: 

 The drug or its sole active ingredient is specifically listed on the P list: Acutely 

Hazardous Waste (40 CFR 261.33(e)) or the U list: Discarded Commercial 

Chemical Products (40 CFR 261.33(f)); and/or 

 The waste exhibits one or more hazardous waste characteristic as defined in 40 

CFR 261.21-24, (ignitability, corrosivity, reactivity, or toxicity). 

Furthermore, 40 CFR 261.11 outlines the criteria for listing a waste as acutely hazardous (i.e., P 

list). A waste is acutely hazardous if it has been found to be fatal to humans in low doses or, in 

the absence of data on human toxicity, the waste has been shown in studies to meet certain lethal 

dose (LD)50 (lethal dose that kills 50 percent of animals tested) or lethal concentration (LC)50

(lethal concentration that kills 50 percent of animals tested) values, or is otherwise capable of 

causing or significantly contributing to an increase in serious irreversible, or incapacitating 

reversible, illness. A drug is acutely hazardous waste if it meets one or more of the following 

LD50 and LC50 values:

 Oral LD50 toxicity (in rats) of less than 50 milligrams per kilogram (mg/kg);

 Inhalation LC50 toxicity (in rats) of less than 2 milligrams per liter (mg/L); or

 Dermal LD50 toxicity (in rabbits) of less than 200 mg/kg. 
3-1

3. IDENTIFICATION OF HAZARDOUS DRUGS AND REVIEW OF TOXICITY DATA

To identify the drugs for this project’s data collection and review, ERG compiled a list of drugs 

based on the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 

2010; a list of hazardous drugs developed by OSHA and included in the OSHA Technical 

Manual (effective date: January 1, 1999); and 32 drug chemicals proposed for addition to the 

NIOSH list. ERG identified 204 unique drugs using these three data sources. One drug, Arsenic 

trioxide, is already included on the P list of hazardous wastes; therefore, ERG did not collect any 

data for it. The NIOSH lists included “Ergonovine/ Methylergonovine” and “Valproic 

acid/Divalproex Sodium (Na)”; however, since each drug has a unique CASRN, ERG captured 

information for those drugs individually. ERG identified an additional drug, Denileukin diftitox2,

during the project. Appendix A includes the list of drugs ERG evaluated under this project.

3.1 NIOSH List of Hazardous Drugs

The list of hazardous drugs presented in the NIOSH List of Antineoplastic and Other Hazardous 

Drugs in Healthcare Settings 2010 comes from two evaluations. NIOSH published the 

evaluation that identified the majority of the drugs in a September 2004 Alert, titled Preventing 

Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Healthcare Settings.

3

Appendix A of the Alert includes a sample list of hazardous drugs compiled from information 

received from the following:

 Four institutions that have generated lists of hazardous drugs for their respective 

facilities

 The Pharmaceutical Research and Manufacturers of America (PhRMA)

 The American Hospital Formulary Service Drug Information (AHFS DI) 

monographs (American Society of Health-System Pharmacists [ASHP]/AHFS DI,

2003)

For the 2004 Alert, drugs considered hazardous included those that exhibit one or more of the 

following six characteristics in humans or animals:

1. Carcinogenicity 

2. Teratogenicity or other developmental toxicity

3. Reproductive toxicity

4. Organ toxicity at low doses

5. Genotoxicity

6. Structure and toxicity profiles of new drugs that mimic existing drugs determined 

hazardous by the above criteria.

NIOSH’s second evaluation identified an additional 21 drugs that were new drugs or existing 

drugs that had new warnings from 2004 to 2007. The review process for the addition of the new 

 

2 Denileukin was listed by NIOSH, however, ERG could not locate a CASRN for it. The National Library of 

Medicine (NLM) and U.S. Food and Drug Administration (FDA) sources, as well as the AHFS DI monograph, 

listed Denileukin diftitox (173146-27-5), but not Denileukin. Therefore, ERG added Denileukin diftitox to the list of 

drugs.

3 NIOSH’s Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Healthcare 

Settings can be accessed at http://www.cdc.gov/niosh/docs/2004-165/.
3-2

listings is described in the Federal Register (74 FR 19570, April 29, 2009). NIOSH reviewed the 

following:

 60 new FDA-approved drugs

 60 drugs that received special warnings on reported adverse effects in patients 

 18 drugs included in the updated National Institutes of Health (NIH) Hazardous 

Drug List

After expert review, scientific literature review, public comments, and stakeholder input, NIOSH 

identified 24 drugs4that met the NIOSH definition of hazardous drugs. In addition, NIOSH 

removed one drug from the 2004 list.

3.2 OSHA List of Hazardous Drugs

The list of hazardous drugs presented in the OSHA Technical Manual Section VI: Chapter 2 –

Controlling Occupational Exposure to Hazardous Drugs is not intended as an all-inclusive list. 

The sources for the list include the Physicians Desk Reference, Section 10:00 in the American 

Hospital Formulary Service Drug Information; International Agency for Research on Cancer 

(IARC) publications (particularly Volume 50); The Johns Hopkins Hospital; and the NIH

Clinical Center Nursing Department. The list does not include investigational drugs, but the 

manual notes that “they should be prudently handled as hazardous drugs until adequate 

information becomes available to exclude them” (OSHA, 1999).

The OSHA Technical Manual provides criteria for classifying drugs as hazardous and cites the 

ASHP hazardous drug definition. The manual lists two ways to classify drugs as hazardous: 1) 

based on characteristic; or 2) based on pharmacology/toxicology. The manual defines the four 

drug characteristics, each of which could be considered hazardous, as the following: 

 Carcinogenicity 

 Teratogenicity or fertility impairment 

 Serious organ or other toxic manifestation at low doses in experimental animals or 

treated patients 

 Genotoxicity 

The manual includes the following major considerations by professionals trained in 

pharmacology/toxicology in designating drugs as hazardous: 

 Is the drug designated as Therapeutic Category 10:00 (Antineoplastic Agent) in 

the AHFS DI? 

 Does the manufacturer suggest the use of special isolation techniques in its 

handling, administration, or disposal? 

 Is the drug known to be a human mutagen, carcinogen, teratogen, or reproductive 

toxicant? 

 

4 The 2010 document stated that only 21 drugs were added; this may have been based on information received by 

NIOSH following the 2009 notice.
3-3

 Is the drug known to be carcinogenic or teratogenic in animals (drugs known to be 

mutagenic in multiple bacterial systems or animals should also be considered 

hazardous)? 

 Is the drug known to be acutely toxic to an organ system? 

3.3 Proposed Additions and Deletions to the NIOSH Hazardous Drug List

In July 2011, NIOSH requested comments on proposed additions and deletions to its list of 

hazardous drugs to be included in the NIOSH List of Antineoplastic and Other Hazardous Drugs 

in Healthcare Settings 2012 (NIOSH, 2011). To identify potential new drugs to add to the list, 

NIOSH looked at the 48 new drugs that received FDA approval between June 2007 and 

December 2009 and 115 drugs that received special warnings (usually black box warnings) 

based on reported adverse effects in patients. NIOSH identified 45 drugs from the list of 169 

drugs as candidate hazardous drugs. Seven of these drugs had safe handling instructions from its 

manufacturers, and NIOSH decided to add these seven drugs without further review. NIOSH 

asked a panel of peer reviewers and stakeholders to review and comment on the remaining 38 

candidate hazardous drugs. After receiving the panel recommendations, NIOSH decided to add 

24 drugs in addition to the 7 drugs with manufacturer’s warnings. NIOSH determined that these 

24 drugs have one or more characteristic of a hazardous drug. 

As part of its update to the list of hazardous drugs, NIOSH proposed to delete 15 drugs from its 

2010 list and requested its panel members to comment on the deletions. The proposed deletions 

include the following:

 Four drugs reclassified as not meeting the criteria for a hazardous drug: Alemtuzumab, 

Interferon alfa 2a, Interferon alfa 2b, and Interferon alfa n3 (all antineoplastic agents).

 Two radio-pharmaceuticals with specific handling regulations set by the Nuclear 

Regulatory Commission: Ibritumomab tiuxetan and Tositumomab (both antineoplastic 

agents).

 Nine others currently not available in the United States: Dienestrol and Trimetrexate 

glucuronate (not antineoplastic agents) and Interferon alfa n1, Perphosphamide, 

Piritrexim isethionate, Plicamycin, Prednumustine, Raltitrexed, and Vindesine 

(antineoplastic agents) (NIOSH, 2011b).

3.4 Collection of Toxicity Data

ERG collected formulary and toxicity information for the 204drugs listed in Appendix A of this 

document. ERG compiled the data into the Microsoft ExcelTM spreadsheet, ORCR Drug

Data.xlsx, and included the spreadsheet as Appendix B of this report. The following subsections 

of this report describe the data sources ERG used for the toxicity data collection, the approach 

ERG used to collect the data, and ERG’s design of the ORCR drug data spreadsheet.

3.4.1 Data Sources 

ERG searched for formulary information, lethal doses, and toxicity information for each drug. 

Table 3-1 presents the data sources ERG used to identify formulary data. In addition, ERG 
3-4

reviewed the 2011 AHFS DI catalog to supplement formulary information (use, route, form, 

strength, brand name) when information was not available in the data sources below. 

Table 3-1. Sources of Formulary Information

Source Formulary Information Website

NLM ChemIDplus  CASRN http://chem.sis.nlm.nih.gov/chemidplus/

chemidlite.jsp

FDA Drugs@FDA  Generic name

 Proprietary/brand name

 Active ingredient

 Strengths or concentrations

 Dose form and route

 Marketing status

http://www.accessdata.fda.gov/scripts/c

der/drugsatfda/index.cfm

NLM MedlinePlus  Drug use

 Use route

 Brand name

http://www.nlm.nih.gov/medlineplus/dr

uginformation.html

In consideration of the definitional requirements for determining “hazardous” as it relates to

RCRA §261.11, ERG specifically searched for human and animal lethal dose data in the sources 

identified in Table 3-2. All sources provide the toxicity value type, species, route of exposure, 

dose, and primary source of the data (reference listed by the secondary source). ERG also 

captured the secondary source (i.e., Hazardous Substances Data Bank [HSDB], ChemIDplus, 

Registry of Toxic Effects of Chemical Substances [RTECS]) for each toxicity value. The 

primary sources are listed for reference purposes; ERG did not obtain and review the primary 

sources to ensure accuracy of the information presented in the secondary sources. 

Table 3-2. Sources of Lethal Dose Data

Source Website

NLM HSDB http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB

NLM ChemIDplus http://chem.sis.nlm.nih.gov/chemidplus/chemidlite.jsp

NIOSH RTECS Through ERG’s Dialog subscription

To supplement the lethal toxicity data, ERG searched data sources listed in Table 3-3 for 

additional non-lethal toxicity information.

Table 3-3. Sources of Toxicity Information

Source Toxicity Benchmark Value Website

NIOSH 2010 List of 

Antineoplastic and Other 

Hazardous Drugs in 

Healthcare Settings 

 AHFS pharmacologic-therapeutic 

classification

http://www.cdc.gov/niosh/docs/2010-

167/
3-5

Table 3-3. Sources of Toxicity Information

Source Toxicity Benchmark Value Website

EPA, Distributed StructureSearchable Toxicity 

(DSSTox)

 Therapeutic category

 Maximum Recommended Daily 

Dose (MRDD)

http://www.epa.gov/ncct/dsstox/sdf_fda

mdd.html

FDA  Maximum Recommended 

Therapeutic Dose (MRTD)

http://www.fda.gov/aboutfda/centersoffi

ces/cder/ucm092199.htm

IARC  Cancer classification http://monographs.iarc.fr/ENG/Classific

ation/index.php

National Toxicology 

Program (NTP) 12th Report 

on Carcinogens (RoC)

 Cancer assessment http://ntp.niehs.nih.gov/index.cfm?objec

tid=03C9AF75-E1BF-FF40-

DBA9EC0928DF8B15

University of California, 

Berkeley Lab Carcinogenic 

Potency Database (CPDB)

 Tumorigenic dose (TD50) for rats

 TD50 for mice

 TD50 for rhesus monkeys

 TD50 for cynomulgus monkeys

 TD50 for hamsters

http://potency.berkeley.edu/chemnamein

dex.html

RTECS  Compound class (tumorigen, 

mutagen, primary irritant, 

reproductive effector)

 Substance name

Through ERG’s Dialog subscription

EPA, National Center for 

Environmental Assessment 

(NCEA), Integrated Risk 

Information System (IRIS)

 Reference Dose (RfD)

 Reference Concentration (RfC)

 Cancer slope factor (CSF)

 Inhalation unit risk (IUR)

 Cancer classification

http://www.epa.gov/iris/

EPA Office of Water (OW)  Maximum Contaminant Level 

(MCL)

 1-day/10-day Health Advisories 

(HA)

 Drinking Water Equivalent Level 

(DWEL)

 Lifetime Health Advisory (LTHA)

http://www.epa.gov/safewater/mcl.html

http://www.epa.gov/waterscience/drinki

ng/standards/dwstandards.pdf

NIOSH  Immediately Dangerous To Life or 

Health Concentration (IDLH)

 Recommended Exposure Limit 

(REL)

http://www.cdc.gov/niosh/idlh/intridl4.h

tml

http://www.cdc.gov/niosh/npg/

OSHA  Permissible Exposure Limit (PEL) http://www.osha.gov/SLTC/pel/

American Conference of 

Government Industrial 

Hygienists (ACGIH)

 Threshold Limit Value (TLV) ACGIH: 2011 TLVs and Biological 

Exposure Indices (BEIs)

As part of EPA OW development of the contaminant candidate list 3 (CCL3) chemicals, EPA 

collected toxicity and benchmark data. ERG reviewed the EPA OW data and found benchmarks 

for 13 of the drugs reviewed (U.S. EPA, 2007). These benchmarks, from the California Office of 

Environmental Health Hazard Assessment (OEHHA), are also included in the ORCR drug data 

spreadsheet developed for this project.
3-6

3.4.2 Data Collection Approach

ERG searched each data source by the drug name (i.e., generic name), CASRN, and brand name. 

ERG specifically searched for lethal doses in humans and animals that meet the specific criteria 

set forth in §261.11 for acute toxicity (e.g., oral LD50, dermal LD50, and inhalation LC50). When 

available, ERG also captured other lethal doses (e.g., lowest dose causing lethality, [LDL0]). 

3.4.3 Design of Hazardous Drugs Toxicity Data Spreadsheet

ERG collected and managed the data in a Microsoft ExcelTM spreadsheet ORCR Drug Data.xlsx

(see Appendix B). The ORCR drug data spreadsheet includes the following worksheets:

 Data Dictionary – explains the data captured in each worksheet

 Formulary Information – captures formulary information for the drugs

 Toxicity Information – captures non-lethal toxicity information for the drugs

 Lethal Doses – captures lethal dose data

 Drug Tiers – contains the tier assignment for each drug (see Section 3.4)

 OW OEHHA – contains the OEHHA benchmarks as captured by EPA OW

3.5 Review of Lethal Toxicity Data

Following the collection of lethality data, ERG categorized each drug into one of the following 

EPA-defined tiers.

Tier 1: Drugs on the NIOSH or OSHA lists of hazardous drugs with evidence of a low lethal 

dose in humans or lethal doses that meet the specific criteria set forth in §261.11 for acute 

toxicity, i.e., oral LD50 (rat), dermal LD50 (rabbit), or inhalation LC50 (rat). 

ERG assigned Tier 1 to any drug found to have lethal animal toxicity data that meets the 

following criteria:

 An oral LD50 in rats less than 50 mg/kg

 An inhalation LC50 in rats less than 2 mg/L

 A dermal LD50 in rabbits less than 200 mg/kg

ERG identified 11 drugs as Tier 1. Three of these drugs are already included on the 

federal RCRA list of hazardous chemicals (U list): 

 Carmustine (154-93-8)

 Cisplatin (15663-27-1)

 Colchicine (64-86-8)

 Dactinomycin (50-76-0)

 Mechlorethamine (51-75-2)

 Melphalan (148-82-3) – EPA 

Waste Code U150

 Mitomycin (50-07-7) – EPA Waste 

Code U010

 Mitoxantrone HCl (70476-82-3)

 Oxytocin (50-56-6)

 Thiotepa (52-24-4)

 Uracil mustard (66-75-1) – EPA 

Waste Code U237

Tier 2: Drugs on the NIOSH or OSHA lists that do not meet the specific criteria in §261.11 for 

acute toxicity, but have lethal doses for other animals comparable to criteria in §261.11 or 

evidence for documented toxicity in humans at “low” doses for carcinogenicity, 
3-7

teratogenicity or other developmental toxicity, reproductive toxicity, or specific organ 

toxicity.

ERG assigned Tier 2 to any non-Tier 1 drug found to have lethal animal or human 

toxicity data outside the criteria set forth in §261.11. NIOSH already determined that all 

drugs on its 2010 List of Antineoplastic and Other Hazardous Drugs in Healthcare 

Settings exhibit one or more of the following six characteristics in humans or animals:

1. Carcinogenicity

2. Teratogenicity or other developmental toxicity

3. Reproductive toxicity

4. Organ toxicity at low doses

5. Genotoxicity 

6. Structure and toxicity profiles of new drugs that mimic existing drugs determined 

hazardous by the above criteria

The drugs on OSHA’s list are considered hazardous by the following criteria:

1. Genotoxicity;

2. Carcinogenicity;

3. Teratogenicity or fertility impairment; or 

4. Serious organ or other toxic manifestation at low doses in experimental animals or 

treated patients

Therefore, documented evidence of toxicity exists for the drugs investigated for this 

project. ERG identified 114 drugs as Tier 2 (see Appendix B). Two of the 114 drugs 

(Docetaxel and Mycophenolic acid) were categorized as Tier 2 drugs based on one of the 

CASRNs; the drugs fall into the Tier 3 category based on the other CASRN. Seventeen of 

the 114 Tier 2 drugs have very little lethality data (borderline Tier 3). One of the 114 Tier 

2 drugs almost meets the Tier 1 criteria (Podofilox [518-28-5]).

Tier 3: Drugs on the NIOSH or OSHA lists that have limited human or animal data for the 

classes of toxicities noted above. 

ERG assigned Tier 3 to any drug that does not have lethality data. ERG identified 79 

drugs as Tier 3 (see Appendix B). Two additional drugs (Docetaxel and Mycophenolic 

acid) were categorized as Tier 3 drugs based on one of the CASRNs; but were 

categorized as Tier 2 drugs based on the other CASRN. Denileukin diftitox (173146-27-

5) was not originally included on either the NIOSH or OSHA list; however, no lethality 

data were available for the drug, and, therefore, ERG categorized it as a Tier 3 drug.
4-1

4. EXTENT OF DRUG USE AND CURRENT DISPOSAL PRACTICES

ERG performed a cursory review of publicly available information (secondary data) to gather 

data on the extent of drug use for the 204 drugs included in Appendix A. A more exhaustive 

literature search might produce more detailed and thorough results. This section of the report

presents the data ERG found on the extent of use for the drugs and an overview of current drug 

disposal practices at healthcare facilities.

4.1 Extent of Drug Use

ERG reviewed two lists of commonly prescribed drugs (top 300 in 2005 and top 200 in 2009) 

and production data from the Chemical Update System/Inventory Update Rule (CUS/IUR) to 

determine if any of the 204 reviewed drugs were commonly prescribed or manufactured. Table 

4-1 lists the Appendix A drugs that were also commonly prescribed in 2005 and 2009 (RX List,

Inc., 2011 and Pharmacy Times, 2010). Four drugs fall on both lists and none are antineoplastic 

agents: Estrogens, conjugated (12126-59-9), Ethinyl estradiol (57-63-6), Risperidone (106266-

06-2), and Divalproex Na (76584-70-8). In 2005, only one antineoplastic agent was on the list; 

however in 2009, 12 antineoplastic agents made the top 200 brand names prescribed.

Table 4-2 lists the production volume reported in the 2006 CUS/IUR database for four drugs 

reviewed by ERG (U.S. EPA, 2006). Because some of the drugs reviewed for this project are 

more recently developed drugs, the majority did not have production data reported in the 

CUS/IUR database. In addition, drugs may be manufactured outside the United States and 

imported for use.
4-2

Table 4-1. Commonly Prescribed Drugs in 2005 and 2009

Appendix A Drugs in the Top 200 Drugs Prescribed in 2009 Appendix A Drugs in the Top 300 Drugs Prescribed in 2005

Drug (Brand) Name CASRN Drug (Brand) Name CASRN

Antineoplastic Agents Antineoplastic Agents

Anastrozole (Arimidex®) 120511-73-1 Tamoxifen (NA) 10540-29-1

Bortezomib (Velcade®) 179324-69-7

Capecitabine (Xeloda®) 154361-50-9 Non-Antineoplastic Agents

Docetaxel (Taxotere®) 148408-66-6; 114977-

28-5

Colchicine (NA) 64-86-8

Gemcitabine (Gemzar®) 95058-81-4 Estradiol (Vivelle-DOT®) 50-28-2

Imatinib mesylate (Gleevec®) 220127-57-1 Estrogens, conjugated (Premarin®) 12126-59-9

Letrozole (Femara®) 112809-51-5

Oxaliplatin (Eloxatin®) 61825-94-3 Estrogens, conjugated & 

Medroxyprogesterone acetate (Prempro®)

12126-59-9

& 

71-58-9

Paclitaxel (Abraxane®) 33069-62-4

Pemetrexed (Alimta®) 137281-23-3

Sunitinib malate (Sutent®) 341031-54-7 Ethinyl estradiol, with Norgestimate and 

Norethindrone

57-63-6

Temozolomide (Temodar®) 85622-93-1 Finasteride (Proscar®) 98319-26-7

Medroxyprogesterone (NA) 520-85-4

Non-Antineoplastic Agents Paroxetine HCl (Paxil CR®) 78246-49-8

Dutasteride (Avodart®) 164656-23-9 Progesterone (Prometrium®) 57-83-0

Estrogens, conjugated (Premarin®) 12126-59-9 Risperidone (Risperdal®) 106266-06-2

Ethinyl estradiol, with Norgestimate 

(Ortho Tri Cy Lo 28®)

57-63-6 Carbamazepine 298-46-4

Risperidone (Risperdal Consta®) 106266-06-2 Clonazepam 1622-61-3

Tacrolimus (Prograf®) 109581-93-3; 

104987-11-3

Oxcarbazepine 28721-07-5

Testosterone (Androgel® 1%) 58-22-0 Simvastatin 79902-63-9

Divalproex Na (Depakote ER® and Divalproex Sodium 

ER®)

76584-70-8 Divalproex Na 76584-70-8

Zoledronic acid (Reclast® and Zometa®) 118072-93-8

Source: RX List, Inc., 2011; Pharmacy Times, 2010

NA – not applicable
4-3

Table 4-2. U.S. Production Ranges for Appendix A Drugs

U.S. Production Range Appendix A Drugs

Less than 500,000 pounds (lbs) Estradiol (50-28-2)

Ethinyl estradiol (57-63-6)

1 to less than 10 million lbs Mercaptopurine (50-44-2; 6112-76-1)

1 billion lbs and greater Fluoxymesterone (76-43-7)

Source: U.S. EPA, 2006

ERG did not perform a separate data search to determine if the drugs are commonly combined 

with other active ingredients or compounds. However, from the data collected, there are a few 

examples in which drugs are commonly combined with other active ingredients or compounds. 

As noted in Table 4-1, Ethinyl estradiol may be combined with Norgestimate, Norethindrone, or 

Norgestral and the brand name Prempro® contains Estrogens, conjugated and

Medroxyprogesterone acetate. The formulary data in Appendix B also lists whether the drug is 

present in medications with other active ingredients.

4.2 Current Drug Disposal Practices

Current drug disposal practices at healthcare facilities depend on multiple factors, including type 

of facility (large facilities such as pharmacies or hospitals versus small facilities such as longterm care facilities or medical offices), form of the drug (e.g., liquid or solid), and current 

regulations. The primary disposal practices for drug wastes include: reverse distribution, 

collection with municipal trash or collection by waste hauler, and down the drain (U.S. EPA, 

2008c). Table 4-3 provides a brief description of these disposal practices and factors that affect 

how facilities select which disposal practice to use.
4-4

Table 4-3. Current Drug Disposal Practices at Healthcare Facilities

Disposal 

Practice Description (U.S. EPA, 2008b) Type of Facilities

Type of Drug

(ERG, 2009)

Regulations Affecting 

Disposal Practice

Reverse 

Distribution

Method used by healthcare facilities to 

receive credit from the pharmaceutical 

manufacturer prior to disposal. The reverse 

distributor determines which medications 

can receive credit from the manufacturer 

and then arranges for disposal of the drug 

waste. The drug is then disposed of via 

incineration or landfill (see below 

discussion of solid waste disposal). 

Larger facilities: Pharmacies and 

hospitals

Most, if not all, large hospitals use 

reverse distribution for unused 

pharmaceuticals that are potentially 

creditable (U.S. EPA, 2009).

Typically solid dose 

forms or unopened 

containers (e.g., past 

expiration date).

Controlled Substances Act 

(CSA) – limits transfer of 

controlled substances between 

Drug Enforcement 

Administration (DEA)-

registrants.

Solid Waste 

Disposal 

Solid waste disposal includes collection of 

everyday trash from healthcare facilities 

and collection of drug and other medical 

waste by a waste hauler. The solid waste is 

either disposed in a landfill or incinerated.

Facilities may also include drug waste in 

their biohazardous (red bag) waste which is 

either sterilized and landfilled or 

incinerated.

Larger facilities, such as hospitals, 

pharmacies, and large medical 

clinics are more likely to have a 

drug waste management program 

and a contract with a waste hauler 

who specializes in drug waste (U.S. 

EPA, 2008b).

Smaller facilities may choose to 

dispose of solid dose drug wastes in 

the regular trash (noncontrolled 

substance). To prevent disposal 

down the drain, smaller facilities 

might mix controlled substances 

with coffee grounds, kitty litter, etc. 

to render irretrievable.

May be liquids in 

addition to solids

Collection and disposal must 

meet RCRA (or state) 

hazardous requirements for 

listed drugs. 

CSA limits transfer of 

controlled substances between 

DEA-registrants; if not a DEAregistrant, the controlled 

substance must be rendered 

irretrievable to prevent 

diversion control.

Chemotherapy wastes also have 

special requirements.

Down the 

Drain

Disposal down the drain is easy to do and a 

low cost way to dispose of drug waste.

Following disposal down the train, the 

wastewater may be treated in a septic tank 

or other onsite treatment system; however, 

this is not common. 

Wastewater from most healthcare facilities 

is collected in a sewer system and 

transported via pipes to a municipal 

wastewater treatment system. 

This method is very common at 

smaller healthcare facilities (ERG, 

2009).

Liquids, such as 

partially-used 

intravenous (IV) 

drugs, are commonly 

disposed down the 

drain, as are solid 

doses for diversion 

control.

Drain disposal also meets the 

DEA requirements for 

controlled substances (U.S. 

EPA, 2008c).

Local wastewater treatment 

systems (e.g., in California) 

may have practices in place to 

limit or ban disposal of drug 

waste down the drain (e.g., 

obtaining permission from 

POTW prior to discharge) (U.S. 

EPA, 2008b).
4-5

4.2.1 Regulations Affecting Drug Disposal Practices

Regulations that affect drug disposal practices include RCRA and CSA. Under CSA, controlled 

substances can only be transferred between DEA-registrants and must be destroyed to prevent 

diversion. Smaller healthcare facilities typically do not have DEA registrations and must dispose 

of controlled substances onsite (DEA, 2011).

The DEA divides controlled substances into five schedules (21 CFR Sections 1308.11 through 

1308.15). DEA places a controlled substance in its respective schedule based on whether it has a 

currently accepted medical use in treatment in the United States and its relative abuse potential 

and likelihood of causing dependence. The definition of the substances in the five schedules 

includes the following (DEA, 2011b):

 Schedule I Controlled Substances have a high potential for abuse, have no currently 

accepted medical use in treatment in the United States, and there is a lack of accepted 

safety for use of the drug or other substance under medical supervision. 

 Schedule II Controlled Substances have a high potential for abuse which may lead to 

severe psychological or physical dependence. Examples of single entity schedule II 

narcotics include morphine and opium. 

 Schedule III Controlled Substances have a potential for abuse less than substances in 

schedules I or II and abuse may lead to moderate or low physical dependence or high 

psychological dependence. 

 Schedule IV Controlled Substances have a low potential for abuse relative to substances 

in schedule III. 

 Schedule V Controlled Substances have a low potential for abuse relative to substances 

listed in schedule IV and consist primarily of preparations containing limited quantities of 

certain narcotics. 

Appendix C includes a list of all controlled substances by schedule for reference purposes. For 

this project, ERG collected toxicity data for five controlled substances. Fluoxymesterone (76-43-

7), Methyltestosterone (58-18-4), Testolactone (968-93-4), and Testosterone (58-22-0) are 

Schedule III controlled substances. Clonazepam (1622-61-3) is a Schedule IV controlled 

substance. 

Drugs that are RCRA or state hazardous drugs must meet transportation and disposal 

requirements protective of the environment and public health. Eight of the drugs in Appendix A

are included on the federal RCRA U list (U.S. EPA, 2008):

 U035: Chlorambucil (305-03-3)

 U058: Cyclophosphamide (50-18-0; 6055-19-2)

 U059: Daunorubicin (as Daunomycin) (20830-81-3)

 U089: Diethylstilbestrol (56-53-1)

 U150: Melphalan (148-82-3)

 U010: Mitomycin (as Mitomycin C) (50-07-7)

 U206: Streptozocin (18883-66-4)

 U237: Uracil mustard (66-75-1)
4-6

All of these drugs, except Diethylstilbestrol, are antineoplastic agents (i.e., chemotherapy drugs). 

In addition to federal regulations, ERG reviewed hazardous waste lists for three states, including 

California, Florida, and North Carolina. California and North Carolina did not list any additional 

Appendix A drugs in their list or summary of RCRA regulations (McGurk, 2002; NCDENR, 

2011). Florida identified three drugs in Appendix A as being hazardous based on meeting the 

ignitability criteria (Waste Code D001): Carmustine (154-93-8), Etoposide (33419-42-0) and 

Paclitaxel (33069-62-4). In addition, Idarubicin (58957-92-9) was listed as 

“Idarubicin/Idamycin” with an EPA waste code of U059 (FLDEP, 2007). All of these drugs are 

also antineoplastic agents. One other antineoplastic agent included on Florida’s list (and the 

federal U list), but not included in Appendix A, is Chlornaphazin (494-03-1), EPA Waste Code 

U026.

4.2.2 Federal Drug Administration’s Recommendations for Flushing Unused Drugs

The FDA published recommendations to consumers on when to flush unused drugs down the 

drain in its document Disposal of Unused Medicines: What You Should Know (FDA, 2010). FDA 

recommends flushing of these drugs due to potential harm to someone from taking the drug 

when not prescribed to them. Table 4-4 includes a list of the drugs recommended for flushing by 

FDA. None of these drugs are currently included on the federal RCRA hazardous waste list and 

ERG did not collect toxicity data for the 14 drugs in Table 4-4. 

Table 4-4. Drugs Recommended for Disposal By Flushing

Active Ingredient Active Ingredient 

CASRN Drug/Brand Name

Acetaminophen/Oxycodone 

Hydrochloride

103-90-2/124-90-3 Percocet

Aspirin/Oxycodone Hydrochloride 50-78-2/124-90-3 Percodan

Diazepam (a) 439-14-5 Diastat/Diastat AcuDial

Fentanyl (a) 437-38-7 Duragesic

Fentanyl Citrate 990-73-8 Actiq; Fentora; Onsolis

Hydromorphone Hydrochloride 71-68-1 Dilaudid; Exalgo

Meperidine Hydrochloride 50-13-5 Demerol

Methadone Hydrochloride 1095-90-5 Dolophine Hydrochloride; Methadose

Methylphenidate (a) 113-45-1 Daytrana

Morphine Sulfate 64-31-3; 6211-15-0 Avinza; Kadian; MS Contin; Oramorph SR

Morphine Sulfate/Naltrexone 

Hydrochloride

64-31-3; 6211-15-0/

16676-29-2

Embeda

Oxycodone Hydrochloride 124-90-3 Oxycontin

Oxymorphone Hydrochloride 357-07-3 Opana; Opana ER

Sodium Oxybate 502-85-2 Xyrem

Source: FDA, 2010. Disposal of Unused Medicines: What You Should Know. March.

a – Drug is a controlled substance.
5-1

5. REFERENCES

1. DEA (Drug Enforcement Administration). 2011. Controlled Substances: Alphabetical 

Order. January 18. Available online at: 

http://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf.

2. DEA.2011b. Controlled Substance Schedules (website). Accessed online September2011 

at: http://www.deadiversion.usdoj.gov/schedules/index.html# Office of Diversion 

Control. 

3. Eastern Research Group (ERG). 2009. Management Practices and Control Technologies 

for Unused Pharmaceuticals at Health Care Facilities – Final, Document Control Number 

06570. October 8. Available at www.regulation.gov: EPA-HQ-OW-2008-0517-0517

4. FDA (Food and Drug Administration). 2010. Disposal of Unused Medicines: What You 

Should Know. March. Available online at: 

http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/E

nsuringSafeUseofMedicine/SafeDisposalofMedicines/ucm186187.htm

5. FLDEP (Florida Department of Environmental Protection). 2007. List of Pharmaceuticals 

that are Potentially Hazardous Wastes When Discarded. Hazardous Waste Regulation 

Section. December 3. Available online at: 

http://www.dep.state.fl.us/waste/quick_topics/publications/shw/hazardous/WastePharmLi

stLetter12_07.pdf.

6. Mcgurk, Jack. 2002. Management of Pharmaceutical Medical Waste. California 

Department of Health and Services. October 15. Available online at: 

http://www.cwea.org/p3s/documents/DHS%20Guidance%20Pharmacy%20Waste%20fro

m%20Hospitals.pdf.

7. NIOSH (National Institute for Occupational Safety and Health). 2010. NIOSH List of 

Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010. Available online 

at: http://www.cdc.gov/niosh/docs/2010-167/.

8. NIOSH. 2011. Notice of Draft Document Available for Public Comment. Available 

online 

at:http://www.cdc.gov/niosh/docket/review/docket190/pdfs/FRNFinal07192011.pdf. 

9. NIOSH. 2011b. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare 

Settings 2012: Proposed Additions and Deletions to the NIOSH Hazardous Drug List. 

Available online at:

http://www.cdc.gov/niosh/docket/review/docket190/pdfs/Proposedchanges07112011.pdf

10. North Carolina Department of the Environment and Natural Resources (DENR). 2011. 

Part 261: Identification and List of Hazardous Wastes. Retrieved July 2011 from: 

http://wastenot.enr.state.nc.us/hwhome/webrules/pdf/0106_1.pdf.

11. OSHA (Occupational Safety and Health Administration).1999. OSHA Technical Manual 

– Effective Date: 1/20/1999; Directive Number: TED 01-00-015. Available online at: 

http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html.

12. Pharmacy Times. 2010. Top 200 Products in the U.S. Market by Sales, 2009. May, p35. 

Available online at: http://www.pharmacytimes.com/media/pdf/PHTM_35.pdf.
5-2

13. RX List, Inc. 2011. Top 300 Prescriptions for 2005. Retrieved June 2011from: 

http://www.rxlist.com/script/main/art.asp?articlekey=79509.

14. U.S. EPA (U.S. Environmental Protection Agency). 2006. Non-confidential 2006 IUR 

Company/Chemical Records. Available online at: 

http://cfpub.epa.gov/iursearch/index.cfm.

15. U.S. EPA. 2007. Microsoft ExcelTM spreadsheet: 

APIUniverse_MRDD_CombinedListing_v3.xls. Office of Water.

16. U.S. EPA. 2008. Hazardous Waste Listings: A User-Friendly Reference Document 

(Draft). Available online at: http://www.epa.gov/wastes/hazard/wastetypes/pdfs/listingref.pdf.

17. U.S. EPA. 2008b. Health Services Industry Study: Management and Disposal of Unused 

Pharmaceuticals (Interim Technical Report). August. Available at www.regulation.gov: 

EPA-HQ-OW-2006-0771-1694.

18. U.S. EPA. 2008c. Unused Pharmaceuticals in the Health Care Industry: Interim Report 

(EPA-821-R-08-010). August. Available online at: 

http://water.epa.gov/scitech/swguidance/ppcp/upload/2010_1_11_ppcp_hcioutreach.pdf.

19. U.S. EPA. 2009. Memorandum: Health Care Industry Study - Meeting with Stericycle, 

July 23, 2009. Office of Water, August 4, 2009. Available at www.regulation.gov: EPAHQ-OW-2008-0517-0333.
Appendix A

LIST OF HAZARDOUS DRUGS REVIEWED BY ERG
A-1

Table A-1. List of Drugs Reviewed by ERG and Tier Assignments

Drug CASRN Source Tier Notes

1 Acitretin 55079-83-9 NIOSH 2011 2 Very little lethality data, 

borderline Tier 3. NIOSH 

proposed as an addition to its

List of Hazardous Drugs.

2 Aldesleukin 110942-02-4 NIOSH 2010 3

3 Alefacept 222535-22-0 NIOSH 2010 3

4 Alemtuzumab 216503-57-0; 

126775-97-1

NIOSH 2010 3 NIOSH proposed deletion from

List of Hazardous Drugs.

5 Alitretinoin 5300-03-8 NIOSH 2010 3

6 Altretamine 645-05-6 NIOSH 2010/OSHA 2

7 Ambrisentan 177036-94-1 NIOSH 2011 3 NIOSH proposed as an addition 

to its List of Hazardous Drugs.

8 Aminoglutethimide 125-84-8 OSHA 2

9 Amsacrine 51264-14-3 NIOSH 2010 2

10 Anastrozole 120511-73-1 NIOSH 2010 3

NA Arsenic trioxide 1327-53-3 NIOSH 2010 NA Already included on the P list 

of hazardous wastes. No 

toxicity data collected.

11 Asparaginase 9015-68-3 NIOSH 2010/OSHA 2

12 Azacitidine 320-67-2 NIOSH 2010 2

13 Azathioprine 446-86-6 NIOSH 2010/OSHA 2

14 Bacillus CalmetteGuerin (BCG)D001500000 NIOSH 2010 3

15 Bendamustine HCl 3543-75-7 NIOSH 2011 2 NIOSH proposed as an addition 

to its List of Hazardous Drugs.

16 Bexarotene 153559-49-0 NIOSH 2010 3

17 Bicalutamide 90357-06-5 NIOSH 2010 2

18 Bleomycin 11056-06-7 NIOSH 2010/OSHA 2

19 Bortezomib 179324-69-7 NIOSH 2010 2

20 Bosentan 147536-97-8 NIOSH 2010 3

21 Busulfan 55-98-1 NIOSH 2010/OSHA 2

22 Cabergoline 81409-90-7 NIOSH 2011 2 Very little lethality data, 

borderline Tier 3. NIOSH 

proposed as an addition to its 

List of Hazardous Drugs.

23 Capecitabine 154361-50-9 NIOSH 2010 2 Very little lethality data, 

borderline Tier 3.

24 Carbamazepine 298-46-4 NIOSH 2011 2 NIOSH proposed as an addition 

to its List of Hazardous Drugs.

25 Carboplatin 41575-94-4 NIOSH 2010/OSHA 2

26 Carmustine 154-93-8 NIOSH 2010/OSHA 1

27 Cetrorelix acetate 145672-81-7 NIOSH 2010 3

28 Chlorambucil 305-03-3 NIOSH 2010/OSHA 2 Already included on the U list 

of hazardous wastes (U035).

29 Chloramphenicol 56-75-7 NIOSH 2010/OSHA 2

30 Chlorotrianisene 569-57-3 OSHA 3

31 Chlorozotocin 54749-90-5 OSHA 2

32 Choriogonadotropin 

alfa

177073-44-8 NIOSH 2010 3

33 Cidofovir 149394-66-1; 

113852-37-2

NIOSH 2010 3

34 Cisplatin 15663-27-1 NIOSH 2010/OSHA 1

35 Cladribine 4291-63-8 NIOSH 2010 2
A-2

Table A-1. List of Drugs Reviewed by ERG and Tier Assignments

Drug CASRN Source Tier Notes

36 Clofarabine 123318-82-1 NIOSH 2010 3

37 Clonazepam 1622-61-3 NIOSH 2011 2 NIOSH proposed as an addition 

to its List of Hazardous Drugs.

38 Colchicine 64-86-8 NIOSH 2010 1

39 Cyclophosphamide 50-18-0; 

6055-19-2

NIOSH 2010/OSHA 2 Already included on the U list 

of hazardous wastes (U058).

40 Cyclosporin 79217-60-0; 

59865-13-3

NIOSH 2010/OSHA 2 Different data were found for 

the CASRN and alternate 

CASRN.

41 Cytarabine 147-94-4 NIOSH 2010/OSHA 2

42 Dacarbazine 4342-03-4 NIOSH 2010/OSHA 2

43 Dactinomycin 50-76-0 NIOSH 2010/OSHA 1

44 Dasatinib 302962-49-8; 

863127-77-9

NIOSH 2010 3

45 Daunorubicin 20830-81-3 OSHA 2 Already included on the U list 

of hazardous wastes (U059).

46 Daunorubicin HCl 23541-50-6 NIOSH 2010 2

47 Decitabine 2353-33-5 NIOSH 2010 2

48 Degarelix 214766-78-6 NIOSH 2011 3 NIOSH proposed as an addition 

to its List of Hazardous Drugs.

49 Denileukin See 

Denileukin 

diftitox

NIOSH 2010 3 ERG could not locate a 

CASRN for Denileukin. The 

NLM and FDA sources as well 

as the AHFS DI monograph 

listed Denileukin diftitox, but 

not Denileukin. Therefore, ERG 

added Denileukin diftitox to the 

list of drugs.

50 Denileukin diftitox 173146-27-5 AHFS 3

51 Dienestrol 84-17-3 NIOSH 2010 3 NIOSH proposed deletion from 

List of Hazardous Drugs.

52 Diethylstilbestrol 56-53-1 NIOSH 2010/OSHA 2 Already included on the U list

of hazardous wastes (U089).

53 Dinoprostone 363-24-6 NIOSH 2010 2

54 Divalproex Na 76584-70-8 NIOSH 2011 3 NIOSH listed “Valproic 

acid/Divalproex Na”; however, 

since each drug has a unique 

CASRN, ERG captured 

information for them 

individually. NIOSH proposed 

as an addition to its List of 

Hazardous Drugs.

55 Docetaxel 148408-66-6; 

114977-28-5

NIOSH 2010 3, 2 Different data were found for 

the CASRN and alternate 

CASRN, resulting in a different 

tier for each (148408-66-6 = 

Tier 3; 114977-28-5 = Tier 2).

56 Doxorubicin 23214-92-8 NIOSH 2010/OSHA 2

57 Dronedarone HCl 141625-93-6 NIOSH 2011 3 NIOSH proposed as an addition 

to its List of Hazardous Drugs.

58 Dutasteride 164656-23-9 NIOSH 2010 3

59 Efavirenz 154598-52-4 NIOSH 2011 3 NIOSH proposed as an addition 

to its List of Hazardous Drugs.

60 Entecavir 142217-69-4 NIOSH 2010 3
A-3

Table A-1. List of Drugs Reviewed by ERG and Tier Assignments

Drug CASRN Source Tier Notes

61 Epirubicin 56420-45-2 NIOSH 2010 2

62 Ergonovine 60-79-7 NIOSH 2010 2 NIOSH listed “Ergonovine/

Methylergonovine”; however, 

since each drug has a unique 

CASRN, ERG captured 

information for them 

individually.

63 Estradiol 50-28-2 NIOSH 2010/OSHA 2 Very little lethality data, 

borderline Tier 3.

64 Estramustine 2998-57-4 OSHA 3

65 Estramustine phosphate 4891-15-0 NIOSH 2010 3

66 Estrogen-progestin 

combinations

NIOSH 2010 3

67 Estrogens, conjugated 12126-59-9 NIOSH 2010 2 Very little lethality data, 

borderline Tier 3.

68 Estrogens, esterified D042724000 NIOSH 2010 3

69 Estrone 53-16-7 NIOSH 2010 2 Very little lethality data, 

borderline Tier 3.

70 Estropipate 7280-37-7 NIOSH 2010 3

71 Ethinyl Estradiol 57-63-6 OSHA 2

72 Etoposide 33419-42-0 NIOSH 2010/OSHA 2

73 Everolimus 159351-69-6 NIOSH 2011 2 Very little lethality data, 

borderline Tier 3. NIOSH 

proposed as an addition to its 

List of Hazardous Drugs.

74 Exemestane 107868-30-4 NIOSH 2010 3

75 Finasteride 98319-26-7 NIOSH 2010 2

76 Floxuridine 50-91-9 NIOSH 2010/OSHA 2

77 Fludarabine 21679-14-1 NIOSH 2010 2 Very little lethality data, 

borderline Tier 3.

78 Fluorouracil 51-21-8 NIOSH 2010/OSHA 2

79 Fluoxymesterone 76-43-7 NIOSH 2010 2 Very little lethality data, 

borderline Tier 3.

80 Flutamide 13311-84-7 NIOSH 2010/OSHA 2

81 Fulvestrant 129453-61-8 NIOSH 2010 3

82 Ganciclovir 82410-32-0 NIOSH 2010/OSHA 2

83 Ganirelix acetate 129311-55-3 NIOSH 2010 3

84 Gemcitabine 95058-81-4 NIOSH 2010 3

85 Gemtuzumab 

ozogamicin

220578-59-6 NIOSH 2010 3

86 Gonadotropin, 

chorionic

9002-61-3 NIOSH 2010 3

87 Goserelin 65807-02-5 NIOSH 2010 3

88 Hydroxyurea 127-07-1 NIOSH 2010/OSHA 2

89 Ibritumomab tiuxetan 206181-63-7 NIOSH 2010 3 NIOSH proposed deletion from 

List of Hazardous Drugs.

90 Idarubicin 58957-92-9 NIOSH 2010/OSHA 2

91 Ifosfamide 3778-73-2; 

84711-20-6

NIOSH 2010/OSHA 2

92 Imatinib mesylate 220127-57-1 NIOSH 2010 3
A-4

Table A-1. List of Drugs Reviewed by ERG and Tier Assignments

Drug CASRN Source Tier Notes

93 Interferon alfa-2a 76543-88-9; 

77907-69-8

NIOSH 2010 2 Different data were found on 

HSDB for the alternate 

CASRN. NIOSH proposed 

deletion from List of Hazardous 

Drugs.

94 Interferon alfa-2b 99210-65-8; 

98530-12-2

NIOSH 2010 2 NIOSH proposed deletion from 

List of Hazardous Drugs.

95 Interferon alfa-n1 308067-63-2 NIOSH 2010 3 NIOSH proposed deletion from 

List of Hazardous Drugs.

96 Interferon alfa-n3 NIOSH 2010 3 NIOSH proposed deletion from 

List of Hazardous Drugs.

97 Interferon-A OSHA 3

98 Irinotecan HCl 100286-90-6; 

136572-09-3

NIOSH 2010 2

99 Isotretinoin 4759-48-2 OSHA 2

100 Ixabepilone 219989-84-1 NIOSH 2011 3 NIOSH proposed as an addition 

to its List of Hazardous Drugs.

101 Leflunomide 75706-12-6 NIOSH 2010 2

102 Lenalidomide 191732-72-6 NIOSH 2010 3

103 Letrozole 112809-51-5 NIOSH 2010 3

104 Leuprolide 53714-56-0 OSHA 3

105 Leuprolide acetate 74381-53-6 NIOSH 2010 2

106 Levamisole 14769-73-4 OSHA 2

107 Lomustine 13010-47-4 NIOSH 2010/OSHA 2

108 Mechlorethamine 51-75-2 NIOSH 2010/OSHA 1

109 Medroxyprogesterone 520-85-4 OSHA 3

110 Medroxyprogesterone 

acetate

71-58-9 NIOSH 2010 2

111 Megestrol 3562-63-8 NIOSH 2010/OSHA 3

112 Melphalan 148-82-3 NIOSH 2010/OSHA 1 Already included on the U list 

of hazardous wastes (U150).

113 Menotropins 9002-68-0; 

61489-71-2

NIOSH 2010 2

114 Mercaptopurine 50-44-2; 

6112-76-1

NIOSH 2010/OSHA 2 Different data were found for 

the CASRN and alternate 

CASRN.

115 Methotrexate 59-05-2 NIOSH 2010/OSHA 2

116 Methylergonovine 113-42-8 NIOSH 2010 2 NIOSH listed “ergonovine/

methylergonovine”; however, 

since each drug has a unique 

CASRN, ERG captured 

information for them 

individually.

117 Methyltestosterone 58-18-4 NIOSH 2010 2

118 Mifepristone 84371-65-3 NIOSH 2010 3

119 Mitomycin 50-07-7 NIOSH 2010/OSHA 1 Already included on the U list 

of hazardous wastes (U010).

120 Mitotane 53-19-0 NIOSH 2010/OSHA 2

121 Mitoxantrone 65271-80-9 OSHA 2

122 Mitoxantrone HCl 70476-82-3 NIOSH 2010 1
A-5

Table A-1. List of Drugs Reviewed by ERG and Tier Assignments

Drug CASRN Source Tier Notes

123 Mometasone furoate 83919-23-7 NIOSH 2011 2 Very little lethality data, 

borderline Tier 3. NIOSH 

proposed as an addition to its 

List of Hazardous Drugs.

124 Mycophenolate mofetil 128794-94-5 NIOSH 2010 3

125 Mycophenolic acid 24280-93-1; 

483-60-3

NIOSH 2011 2,3 Different data were found for 

the CASRN and alternate 

CASRN, resulting in a different 

tier for each (24280-93-1 = Tier 

2; 483-60-3 = Tier 3). NIOSH 

proposed as an addition to its 

List of Hazardous Drugs.

126 Nafarelin 76932-56-4 NIOSH 2010/OSHA 3

127 Nelarabine 121032-29-9 NIOSH 2010 3

128 Nilotinib 641571-10-0 NIOSH 2011 3 NIOSH proposed as an addition 

to its List of Hazardous Drugs.

129 Nilutamide 63612-50-0 NIOSH 2010 2

130 Oxaliplatin 61825-94-3 NIOSH 2010 2 Very little lethality data, 

borderline Tier 3.

131 Oxcarbazepine 28721-07-5 NIOSH 2011 3 NIOSH proposed as an addition 

to its List of Hazardous Drugs.

132 Oxytocin 50-56-6 NIOSH 2010 1

133 Paclitaxel 33069-62-4 NIOSH 2010 2

134 Palifermin 162394-19-6 NIOSH 2010 3

135 Paroxetine HCl 78246-49-8 NIOSH 2010 2

136 Paroxetine mesylate 217797-14-3 NIOSH 2011 3 NIOSH proposed as an addition 

to its List of Hazardous Drugs.

137 Pazopanib HCl 635702-64-6 NIOSH 2011 3 NIOSH proposed as an addition 

to its List of Hazardous Drugs.

138 Pegaspargase 130167-69-0 NIOSH 2010 3

139 Pemetrexed 137281-23-3 NIOSH 2010 3

140 Pentamidine isethionate 140-64-7 NIOSH 2010 2

141 Pentetate calcium 

trisodium

12111-24-9 NIOSH 2010 2

142 Pentostatin 53910-25-1 NIOSH 2010 2

143 Perphosfamide 62435-42-1 NIOSH 2010 3 NIOSH proposed deletion from 

List of Hazardous Drugs.

144 Phenoxybenzamine HCl 63-92-3 NIOSH 2011 2 NIOSH proposed as an addition 

to its List of Hazardous Drugs.

145 Pipobroman 54-91-1 NIOSH 2010/OSHA 2

146 Piritrexim isethionate 79483-69-5 NIOSH 2010 3 NIOSH proposed deletion from 

List of Hazardous Drugs.

147 Pitavastatin Ca 147526-32-7 NIOSH 2011 2 Very little lethality data, 

borderline Tier 3. NIOSH 

proposed as an addition to its 

List of Hazardous Drugs.

148 Plerixafor 110078-46-1 NIOSH 2011 3 NIOSH proposed as an addition 

to its List of Hazardous Drugs.

149 Plicamycin 18378-89-7 NIOSH 2010/OSHA 2 NIOSH proposed deletion from 

List of Hazardous Drugs.

150 Podofilox 518-28-5 NIOSH 2010 2 Has a dermal LD50 in rabbits of 

200 mg/kg, borderline Tier 1.

151 Podophyllum resin 9000-55-9 NIOSH 2010 2
A-6

Table A-1. List of Drugs Reviewed by ERG and Tier Assignments

Drug CASRN Source Tier Notes

152 Pralatrexate 146464-95-1 NIOSH 2011 3 NIOSH proposed as an addition 

to its List of Hazardous Drugs.

153 Prednimustine 29069-24-7 NIOSH 2010 2 NIOSH proposed deletion from 

List of Hazardous Drugs.

154 Procarbazine 671-16-9 NIOSH 2010/OSHA 2

155 Progesterone 57-83-0 NIOSH 2010 2

156 Progestins P097000000 NIOSH 2010 3

157 Raloxifene 84449-90-1 NIOSH 2010 3

158 Raltitrexed 112887-68-0 NIOSH 2010 3 NIOSH proposed deletion from 

List of Hazardous Drugs.

159 Rasagiline mesylate 161735-79-1 NIOSH 2010 3

160 Ribavirin 36791-04-5 NIOSH 2010/OSHA 2

161 Risperidone 106266-06-2 NIOSH 2010 2

162 Romidepsin 128517-07-7 NIOSH 2011 2 Very little lethality data, 

borderline Tier 3. NIOSH 

proposed as an addition to its 

List of Hazardous Drugs.

163 Rufinamide 106308-44-5 NIOSH 2011 3 NIOSH proposed as an addition 

to its List of Hazardous Drugs.

164 Simvastatin 79902-63-9 NIOSH 2011 2 NIOSH proposed as an addition 

to its List of Hazardous Drugs.

165 Sirolimus 53123-88-9 NIOSH 2010 2

166 Sorafenib 284461-73-0 NIOSH 2010 3

167 Streptozocin 18883-66-4 NIOSH 2010/OSHA 2 Already included on the U list 

of hazardous wastes (U206).

168 Sunitinib malate 341031-54-7 NIOSH 2010 3

169 Tacrolimus 109581-93-3; 

104987-11-3

NIOSH 2010 2

170 Tamoxifen 10540-29-1 NIOSH 2010/OSHA 2

171 Telavancin HCl 560130-42-9 NIOSH 2011 3 NIOSH proposed as an addition 

to its List of Hazardous Drugs.

172 Temsirolimus 162635-04-3 NIOSH 2011 3 NIOSH proposed as an addition 

to its List of Hazardous Drugs.

173 Temozolomide 85622-93-1 NIOSH 2010 2 Very little lethality data, 

borderline Tier 3.

174 Teniposide 29767-20-2 NIOSH 2010 2

175 Testolactone 968-93-4 NIOSH 2010/OSHA 3

176 Testosterone 58-22-0 NIOSH 2010 2 Very little lethality data, 

borderline Tier 3.

177 Tetracycline 

hydrochloride

64-75-5 NIOSH 2011 2 NIOSH proposed as an addition 

to its List of Hazardous Drugs.

178 Thalidomide 50-35-1 NIOSH 2010 2

179 Thioguanine 154-42-7 NIOSH 2010/OSHA 2

180 Thiotepa 52-24-4 NIOSH 2010/OSHA 1

181 Topotecan 123948-87-8 NIOSH 2010 3

182 Toremifene citrate 89778-27-8 NIOSH 2010 2

183 Tositumomab 192391-48-3; 

208921-02-2

NIOSH 2010 3 NIOSH proposed deletion from 

List of Hazardous Drugs.

184 Tretinoin 302-79-4 NIOSH 2010 2

185 Trifluridine 70-00-8 NIOSH 2010 2

186 Trimetrexate 

glucuronate

82952-64-5 NIOSH 2010 2 NIOSH proposed deletion from 

List of Hazardous Drugs.

187 Triptorelin 57773-63-4 NIOSH 2010 3
A-7

Table A-1. List of Drugs Reviewed by ERG and Tier Assignments

Drug CASRN Source Tier Notes

188 Uracil mustard 66-75-1 NIOSH 2010/OSHA 1 Already included on the U list 

of hazardous wastes (U237).

189 Valganciclovir 175865-60-8 NIOSH 2010 3

190 Valproic acid 99-66-1 NIOSH 2011 2 NIOSH listed “Valproic 

acid/Divalproex Na”; however, 

since each drug has a unique 

CASRN, ERG captured 

information for them 

individually. NIOSH proposed 

as an addition to its List of 

Hazardous Drugs.

191 Valrubicin 56124-62-0 NIOSH 2010 2 Very little lethality data, 

borderline Tier 3.

192 Vidarabine 24356-66-9; 

5536-17-4

NIOSH 2010/OSHA 2

193 Vigabatrin 60643-86-9 NIOSH 2011 2 NIOSH proposed as an addition 

to its List of Hazardous Drugs.

194 Vinblastine 865-21-4 OSHA 2

195 Vinblastine sulfate 143-67-9 NIOSH 2010 2

196 Vincristine 57-22-7 OSHA 2

197 Vincristine sulfate 2068-78-2 NIOSH 2010 2

198 Vindesine 53643-48-4 NIOSH 2010 2 NIOSH proposed deletion from 

List of Hazardous Drugs.

199 Vinorelbine tartrate 125317-39-7 NIOSH 2010 3

200 Vorinostat 149647-78-9 NIOSH 2010 3

201 Zidovudine 30516-87-1 NIOSH 2010/OSHA 2

202 Ziprasidone HCl 122883-93-6; 

138982-67-9

NIOSH 2011 3 NIOSH proposed as an addition 

to its List of Hazardous Drugs.

203 Zoledronic acid 118072-93-8 NIOSH 2011 2 Very little lethality data, 

borderline Tier 3. NIOSH 

proposed as an addition to its 

List of Hazardous Drugs.

204 Zonisamide 68291-97-4 NIOSH 2010 2
B-1

Appendix B

TOXICITY DATA

(See separate Excel file: ORCR Drug Data.xlsx)
C-1

Appendix C

LIST OF CONTROLLED SUBSTANCES BY DEA SCHEDULE
C-1

Table C-1. Schedule I Controlled Substances

SUBSTANCE

DEA 

NUMBER

CSA 

SCH NARC OTHER NAMES

1-(1-Phenylcyclohexyl)pyrrolidine 7458 I N PCPy, PHP, rolicyclidine

1-(2-Phenylethyl)-4-phenyl-4-

acetoxypiperidine 9663 I Y PEPAP, synthetic heroin

1-[1-(2-

Thienyl)cyclohexyl]piperidine 7470 I N TCP, tenocyclidine

1-[1-(2-

Thienyl)cyclohexyl]pyrrolidine 7473 I N TCPy

1-Methyl-4-phenyl-4-

propionoxypiperidine 9661 I Y MPPP, synthetic heroin

2,5-Dimethoxy-4-(n)-

propylthiophenethylamine 7348 I N 2C-T-7

2,5-Dimethoxy-4-ethylamphetamine 7399 I N DOET

2,5-Dimethoxyamphetamine 7396 I N DMA, 2,5-DMA

3,4,5-Trimethoxyamphetamine 7390 I N TMA

3,4-Methylenedioxyamphetamine 7400 I N MDA, Love Drug

3,4-

Methylenedioxymethamphetamine 7405 I N MDMA, Ecstasy, XTC

3,4-Methylenedioxy-Nethylamphetamine 7404 I N N-ethyl MDA, MDE, MDEA

3-Methylfentanyl 9813 I Y China White, fentanyl

3-Methylthiofentanyl 9833 I Y Chine White, fentanyl

4-Bromo-2,5-

dimethoxyamphetamine 7391 I N DOB, 4-bromo-DMA

4-Bromo-2,5-

dimethoxyphenethylamine 7392 I N

2C-B, Nexus, has been sold as 

Ecstasy, i.e. MDMA

4-Methoxyamphetamine 7411 I N PMA

4-Methyl-2,5-

dimethoxyamphetamine 7395 I N DOM, STP

4-Methylaminorex (cis isomer) 1590 I N U4Euh, McN-422

5-Methoxy-3,4-

methylenedioxyamphetamine 7401 I N MMDA

5-Methoxy-N,Ndiisopropyltryptamine 7439 I N 5-MeO-DIPT

5-Methoxy-N-N-dimethyltryptamine 7431 I N 5-MeO-DMT

Acetorphine 9319 I Y

Acetyl-alpha-methylfentanyl 9815 I Y

Acetyldihydrocodeine 9051 I Y Acetylcodone

Acetylmethadol 9601 I Y Methadyl acetate

Allylprodine 9602 I Y

Alphacetylmethadol except levoalphacetylmethadol 9603 I Y

Alpha-ethyltryptamine 7249 I N ET, Trip

Alphameprodine 9604 I Y

Alphamethadol 9605 I Y

Alpha-methylfentanyl 9814 I Y China White, fentanyl
C-2

Table C-1. Schedule I Controlled Substances

SUBSTANCE

DEA 

NUMBER

CSA 

SCH NARC OTHER NAMES

Alpha-methylthiofentanyl 9832 I Y China White, fentanyl

Alpha-methyltryptamine 7432 I N AMT

Aminorex 1585 I N has been sold as methamphetamine

Benzethidine 9606 I Y

Benzylmorphine 9052 I Y

Betacetylmethadol 9607 I Y

Beta-hydroxy-3-methylfentanyl 9831 I Y China White, fentanyl

Beta-hydroxyfentanyl 9830 I Y China White, fentanyl

Betameprodine 9608 I Y

Betamethadol 9609 I Y

Betaprodine 9611 I Y

Bufotenine 7433 I N Mappine, N,N-dimethylserotonin

Cathinone 1235 I N Constituent of "Khat" plant

Clonitazene 9612 I Y

Codeine methylbromide 9070 I Y

Codeine-N-oxide 9053 I Y

CP-47497 7297 I N

5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-

hydroxycyclohexyl phenol

CP-47497 C8 Homologue 7298 I N

5-(1,1-Dimethyloctyl)-2-[(1R,3S)3-

hydroxycyclohexyl phenol

Cyprenorphine 9054 I Y

Desomorphine 9055 I Y

Dextromoramide 9613 I Y Palfium, Jetrium, Narcolo

Diampromide 9615 I Y

Diethylthiambutene 9616 I Y

Diethyltryptamine 7434 I N DET

Difenoxin 9168 I Y Lyspafen

Dihydromorphine 9145 I Y

Dimenoxadol 9617 I Y

Dimepheptanol 9618 I Y

Dimethylthiambutene 9619 I Y

Dimethyltryptamine 7435 I N DMT

Dioxaphetyl butyrate 9621 I Y

Dipipanone 9622 I Y

Dipipan, phenylpiperone HCl, 

Diconal, Wellconal

Drotebanol 9335 I Y Metebanyl, oxymethebanol

Ethylmethylthiambutene 9623 I Y

Etonitazene 9624 I Y

Etorphine (except HCl) 9056 I Y
C-3

Table C-1. Schedule I Controlled Substances

SUBSTANCE

DEA 

NUMBER

CSA 

SCH NARC OTHER NAMES

Etoxeridine 9625 I Y

Fenethylline 1503 I N

Captagon,amfetyline,ethyltheophylline 

amphetamine

Furethidine 9626 I Y

Gamma Hydroxybutyric Acid 2010 I N

GHB, gamma hydroxybutyrate, 

sodium oxybate

Heroin 9200 I Y Diacetylmorphine, diamorphine

Hydromorphinol 9301 I Y

Hydroxypethidine 9627 I Y

Ibogaine 7260 I N

Constituent of "Tabernanthe iboga" 

plant

JWH-018 (also known as AM678) 7118 I N 1-Pentyl-3-(1-naphthoyl)indole

JWH-073 7173 I N 1-Butyl-3-(1-naphthoyl)indole

JWH-200 7200 I N

1-[2-(4-Morpholinyl)ethyl]-3-(1-

naphthoyl)indole

Ketobemidone 9628 I Y Cliradon

Levomoramide 9629 I Y

Levophenacylmorphan 9631 I Y

Lysergic acid diethylamide 7315 I N LSD, lysergide

Marihuana 7360 I N Cannabis, marijuana

Mecloqualone 2572 I N Nubarene

Mescaline 7381 I N Constituent of "Peyote" cacti

Methaqualone 2565 I N

Quaalude, Parest, Somnafac, Opitimil, 

Mandrax

Methcathinone 1237 I N N-Methylcathinone, "cat"

Methyldesorphine 9302 I Y

Methyldihydromorphine 9304 I Y

Morpheridine 9632 I Y

Morphine methylbromide 9305 I Y

Morphine methylsulfonate 9306 I Y

Morphine-N-oxide 9307 I Y

Myrophine 9308 I Y

N,N-Dimethylamphetamine 1480 I N

N-Benzylpiperazine 7493 I N BZP, 1-benzylpiperazine

N-Ethyl-1-phenylcyclohexylamine 7455 I N PCE

N-Ethyl-3-piperidyl benzilate 7482 I N JB 323

N-Ethylamphetamine 1475 I N NEA

N-Hydroxy-3,4-

methylenedioxyamphetamine 7402 I N N-hydroxy MDA

Nicocodeine 9309 I Y

Nicomorphine 9312 I Y Vilan
C-4

Table C-1. Schedule I Controlled Substances

SUBSTANCE

DEA 

NUMBER

CSA 

SCH NARC OTHER NAMES

N-Methyl-3-piperidyl benzilate 7484 I N JB 336

Noracymethadol 9633 I Y

Norlevorphanol 9634 I Y

Normethadone 9635 I Y Phenyldimazone

Normorphine 9313 I Y

Norpipanone 9636 I Y

Para-Fluorofentanyl 9812 I Y China White, fentanyl

Parahexyl 7374 I N Synhexyl,

Peyote 7415 I N Cactus which contains mescaline

Phenadoxone 9637 I Y

Phenampromide 9638 I Y

Phenomorphan 9647 I Y

Phenoperidine 9641 I Y Operidine, Lealgin

Pholcodine 9314 I Y

Copholco, Adaphol, Codisol, Lantuss, 

Pholcolin

Piritramide 9642 I Y Piridolan

Proheptazine 9643 I Y

Properidine 9644 I Y

Propiram 9649 I Y Algeril

Psilocybin 7437 I N Constituent of "Magic mushrooms"

Psilocyn 7438 I N

Psilocin, constituent of "Magic 

mushrooms"

Racemoramide 9645 I Y

Tetrahydrocannabinols 7370 I N

THC, Delta-8 THC, Delta-9 THC, 

dronabinol and others

Thebacon 9315 I Y

Acetylhydrocodone, Acedicon, 

Thebacetyl

Thiofentanyl 9835 I Y Chine white, fentanyl

Tilidine 9750 I Y Tilidate, Valoron, Kitadol, Lak, Tilsa

Trimeperidine 9646 I Y Promedolum

NARC - Narcotic

Table C-2. Schedule II Controlled Substances

SUBSTANCE

DEA 

NUMBER

CSA 

SCH NARC OTHER NAMES

1-Phenylcyclohexylamine 7460 II N PCP precursor 

1-Piperidinocyclohexanecarbonitrile 8603 II N PCC, PCP precursor 

4-Anilino-N-phenethyl-4-piperidine 

(ANPP) 8333 II N ANPP 

Alfentanil 9737 II Y Alfenta 

Alphaprodine 9010 II Y Nisentil 
C-5

Table C-2. Schedule II Controlled Substances

SUBSTANCE

DEA 

NUMBER

CSA 

SCH NARC OTHER NAMES

Amobarbital 2125 II N Amytal, Tuinal 

Amphetamine 1100 II N Dexedrine, Adderall, Obetrol 

Anileridine 9020 II Y Leritine 

Benzoylecgonine 9180 II Y Cocaine metabolite 

Bezitramide 9800 II Y Burgodin 

Carfentanil 9743 II Y Wildnil 

Coca Leaves 9040 II Y 

Cocaine 9041 II Y Methyl benzoylecgonine, Crack 

Codeine 9050 II Y Morphine methyl ester, methyl 

morphine 

Dextropropoxyphene, bulk (non-dosage 

forms) 9273 II Y Propoxyphene 

Dihydrocodeine 9120 II Y Didrate, Parzone 

Dihydroetorphine 9334 II Y DHE 

Diphenoxylate 9170 II Y 

Ecgonine 9180 II Y Cocaine precursor, in Coca leaves 

Ethylmorphine 9190 II Y Dionin 

Etorphine HCl 9059 II Y M 99 

Fentanyl 9801 II Y Duragesic, Oralet, Actiq, 

Sublimaze, Innovar 

Glutethimide 2550 II N Doriden, Dorimide 

Hydrocodone 9193 II Y dihydrocodeinone 

Hydromorphone 9150 II Y Dilaudid, dihydromorphinone 

Isomethadone 9226 II Y Isoamidone 

Levo-alphacetylmethadol 9648 II Y LAAM, long acting methadone, 

levomethadyl acetate 

Levomethorphan 9210 II Y 

Levorphanol 9220 II Y Levo-Dromoran 

Lisdexamfetamine 1205 II N Vyvanse 

Meperidine 9230 II Y Demerol, Mepergan, pethidine 

Meperidine intermediate-A 9232 II Y Meperidine precursor 

Meperidine intermediate-B 9233 II Y Meperidine precursor, 

normeperidine 

Meperidine intermediate-C 9234 II Y Meperidine precursor 

Metazocine 9240 II Y 

Methadone 9250 II Y Dolophine, Methadose, Amidone 

Methadone intermediate 9254 II Y Methadone precursor 

Methamphetamine 1105 II N Desoxyn, D-desoxyephedrine, 

ICE, Crank, Speed 

Methylphenidate 1724 II N Concerta, Ritalin, Methylin 

Metopon 9260 II Y 
C-6

Table C-2. Schedule II Controlled Substances

SUBSTANCE

DEA 

NUMBER

CSA 

SCH NARC OTHER NAMES

Moramide-intermediate 9802 II Y 

Morphine 9300 II Y MS Contin, Roxanol, Oramorph, 

RMS, MSIR 

Nabilone 7379 II N Cesamet 

Opium extracts 9610 II Y 

Opium fluid extract 9620 II Y 

Opium poppy 9650 II Y Papaver somniferum 

Opium tincture 9630 II Y Laudanum 

Opium, granulated 9640 II Y Granulated opium 

Opium, powdered 9639 II Y Powdered opium 

Opium, raw 9600 II Y Raw opium, gum opium 

Oripavine 9330 II Y 

Oxycodone 9143 II Y OxyContin, Percocet, Endocet, 

Roxicodone, Roxicet, 

Oxymorphone 9652 II Y Numorphan 

Pentobarbital 2270 II N Nembutal 

Phenazocine 9715 II Y Narphen, Prinadol 

Phencyclidine 7471 II N PCP, Sernylan 

Phenmetrazine 1631 II N Preludin 

Phenylacetone 8501 II N P2P, phenyl-2-propanone, benzyl 

methyl ketone 

Piminodine 9730 II Y 

Poppy Straw 9650 II Y Opium poppy capsules, poppy 

heads 

Poppy Straw Concentrate 9670 II Y Concentrate of Poppy Straw, CPS 

Racemethorphan 9732 II Y 

Racemorphan 9733 II Y Dromoran 

Remifentanil 9739 II Y Ultiva 

Secobarbital 2315 II N Seconal, Tuinal 

Sufentanil 9740 II Y Sufenta 

Tapentadol 9780 II Y 

Thebaine 9333 II Y Precursor of many narcotics 

NARC - Narcotic

Table C-3. Schedule III Controlled Substances

SUBSTANCE

DEA 

NUMBER

CSA 

SCH NARC OTHER NAMES

13Beta-ethyl-17beta-hydroxygon-4-en-3-

one 

4000 III N 

17Alpha-methyl-3alpha,17beta-dihydroxy5alpha- androstane 4000 III N 
C-7

Table C-3. Schedule III Controlled Substances

SUBSTANCE

DEA 

NUMBER

CSA 

SCH NARC OTHER NAMES

17Alpha-methyl-3beta,17beta-dihydroxy5alpha- androstane 4000 III N 

17Alpha-methyl-3beta,17betadihydroxyandrost-4-ene 

4000 III N 

17Alpha-methyl-4-hydroxynandrolone 

(17alpha-methyl 4-hydroxy-17betahydroxyestr-4-en-3-one)4000 III N 

17Alpha-methyl-delta1-

dihydrotestosterone (17beta hydroxy17alpha-methyl-5alpha-androst-1-en-3-

one)

4000 III N 17-Alpha-methyl-1-testosterone 

19-Nor-4,9(10)-androstadienedione 4000 III N 

19-Nor-4-androstenediol (3beta,17betadihydroxyestr-4 ene; 3alpha,17betadihydroxyestr-4-ene)

4000 III N 

19-Nor-4-androstenedione (estr-4-en-3,17-

dione) 4000 III N 

19-Nor-5-androstenediol (3beta,17betadihydroxyestr-5 ene; 3alpha,17betadihydroxyestr-5-ene)

4000 III N 

19-Nor-5-androstenedione (estr-5-en-3,17-

dione) 4000 III N 

1-Androstenediol (3beta,17betadihydroxy-5alpha androst-1-ene; 

3alpha,17beta-dihydroxy-5alpha androst1-ene)

4000 III N 

1-Androstenedione (5alpha-androst-1-en3,17-dione) 4000 III N 

3Alpha,17beta-dihydroxy-5alphaandrostane 4000 III N 

3Beta,17beta-dihydroxy-5alphaandrostane 4000 III N 

4-Androstenediol (3beta,17betadihydroxy-androst-4 ene) 4000 III N 4-AD 

4-Androstenedione (androst-4-en-3,17-

dione) 4000 III N 

4-Dihydrotestosterone (17betahydroxyandrostan-3 one) 4000 III N Anabolex, Andractim, Pesomax, 

Stanolone 

4-Hydroxy-19-nortestosterone (4,17betadihydroxyestr 4-en-3-one) 4000 III N 

4-Hydroxytestosterone (4,17betadihydroxyandrost-4 en-3-one) 4000 III N 

5-Androstenediol (3beta,17betadihydroxy-androst-5 ene) 4000 III N 

5-Androstenedione (androst-5-en-3,17-

dione) 4000 III N 

Amobarbital & noncontrolled active 

ingred. 2126 III N 

Amobarbital suppository dosage form 2126 III N 

Anabolic steroids 4000 III N "Body Building" drugs 

Androstanedione (5alpha-androstan-3,17-

dione) 4000 III N 
C-8

Table C-3. Schedule III Controlled Substances

SUBSTANCE

DEA 

NUMBER

CSA 

SCH NARC OTHER NAMES

Aprobarbital 2100 III N Alurate 

Barbituric acid derivative 2100 III N Barbiturates not specifically listed 

Benzphetamine 1228 III N Didrex, Inapetyl 

Bolasterone (7alpha,17alpha-dimethyl17beta hydroxyandrost-4-en-3-one) 4000 III N 

Boldenone (17beta-hydroxyandrost-1,4-

diene-3-one) 4000 III N Equipoise, Parenabol, Vebonol, dehydrotestosterone 

Boldione 4000 III N 

Buprenorphine 9064 III Y

Buprenex, Temgesic, Subutex, 

Suboxone 

Butabarbital (secbutabarbital) 2100 III N Butisol, Butibel 

Butalbital 2100 III N Fiorinal, Butalbital with aspirin 

Butobarbital (butethal) 2100 III N Soneryl (UK) 

Calusterone (7beta,17alpha-dimethyl17beta hydroxyandrost-4-en-3-one) 4000 III N Methosarb 

Chlorhexadol 2510 III N Mechloral, Mecoral, Medodorm, 

Chloralodol 

Chlorphentermine 1645 III N Pre-Sate, Lucofen, Apsedon, 

Desopimon 

Clortermine 1647 III N Voranil 

Clostebol (4-chloro-17betahydroxyandrost-4-en-3-one) 4000 III NAlfa-Trofodermin, Clostene, 4-

chlorotestosterone 

Codeine & isoquinoline alkaloid 90 mg/du 9803 III Y Codeine with papaverine or 

noscapine 

Codeine combination product 90 mg/du 9804 III Y Empirin,Fiorinal,Tylenol,ASA or 

APAP w/codeine 

Dehydrochloromethyltestosterone (4-

chloro-17beta hydroxy-17alphamethylandrost-1,4-dien-3-one)4000 III N Oral-Turinabol 

Delta1-dihydrotestosterone (17betahydroxy-5alpha androst-1-en-3-one) 4000 III N 1-Testosterone 

Desoxymethyltestosterone 4000 III N 

Dihydrocodeine combination product 90 

mg/du 9807 III Y Synalgos-DC, Compal 

Dronabinol (synthetic) in sesame oil in 

soft gelatin capsule as approved by FDA 7369 III N 

Marinol, synthetic THC in sesame 

oil/soft gelatin as approved by 

FDA

Drostanolone (17beta-hydroxy-2alphamethyl-5alpha androstan-3-one) 4000 III N Drolban, Masterid, Permastril 

Embutramide 2020 III N Tributane 

Ethylestrenol (17alpha-ethyl-17betahydroxyestr-4-ene) 4000 III N Maxibolin, Orabolin, Durabolin-O, 

Duraboral 

Ethylmorphine combination product 15 

mg/du 9808 III Y 

Fluoxymesterone (9-fluoro-17alphamethyl11beta,17beta-dihydroxyandrost-4-

en-3-one) 

4000 III N Anadroid-F, Halotestin, OraTestryl 

Formebolone (2-formyl-17alpha-methyl11alpha,17beta-dihydroxyandrost-1,4-

dien-3-one) 

4000 III N Esiclene, Hubernol 

Furazabol (17alpha-methyl-17betahydroxyandrostano[2,3-c]-furazan) 4000 III N Frazalon, Miotolon, Qu Zhi Shu 
C-9

Table C-3. Schedule III Controlled Substances

SUBSTANCE

DEA 

NUMBER

CSA 

SCH NARC OTHER NAMES

Gamma Hydroxybutyric Acid preparations 2012 III N Xyrem 

Hydrocodone & isoquinoline alkaloid <15 

mg/du 9805 III Y Dihydrocodeinone+papaverine or noscapine 

Hydrocodone combination product <15 

mg/du 9806 III Y Lorcet, Lortab,Vicodin, Vicoprofen,Tussionex, Norco 

Ketamine 7285 III N Ketaset, Ketalar, Special K, K 

Lysergic acid 7300 III N LSD precursor 

Lysergic acid amide 7310 III N LSD precursor 

Mestanolone (17alpha-methyl-17betahydroxy-5alphaandrostan-3-one) 4000 III N Assimil, Ermalone, Methybol, 

Tantarone 

Mesterolone (1alpha-methyl-17betahydroxy-5alphaandrostan-3-one) 4000 III N Androviron, Proviron, Testiwop 

Methandienone (17alpha-methyl-17betahydroxyandrost-1,4-diene-3-one) 4000 III N Dianabol, Metabolina, Nerobol, 

Perbolin 

Methandriol (17alpha-methyl3beta,17betadihydroxyandrost-5-ene) 4000 III N Sinesex, Stenediol, Troformone 

Methenolone (1-methyl-17beta-hydroxy5alpha-androst1-en-3-one) 4000 III N Primobolan, Primobolan Depot, 

Primobolan S 

Methyldienolone (17alpha-methyl-17betahydroxyestr4,9(10)-dien-3-one) 4000 III N 

Methyltestosterone (17alpha-methyl17betahydroxyandrost-4-en-3-one) 4000 III N Android, Oreton, Testred, Virilon 

Methyltrienolone (17alpha-methyl-17betahydroxyestr4,9,11-trien-3-one) 4000 III N Metribolone 

Methyprylon 2575 III N Noludar 

Mibolerone (7alpha,17alpha-dimethyl17betahydroxyestr-4-en-3-one) 4000 III N Cheque, Matenon 

Morphine combination product/50 mg/100 

ml or gm 9810 III Y 

Nalorphine 9400 III Y Nalline 

Nandrolone (17beta-hydroxyestr-4-en-3-

one) 4000 III N Deca-Durabolin, Durabolin, Durabolin-50 

Norbolethone (13beta,17alpha-diethyl17betahydroxygon-4-en-3-one) 4000 III N Genabol 

Norclostebol (4-chloro-17betahydroxyestr-4-en-3-one 

4000 III N Anabol-4-19, Lentabol 

Norethandrolone (17alpha-ethyl-17betahydroxyestr-4en-3-one) 4000 III N Nilevar, Pronabol, Solevar 

Normethandrolone (17alpha-methyl17betahydroxyestr-4-en-3-one) 4000 III N Lutenin, Matronal, Orgasteron 

Opium combination product 25 mg/du 9809 III Y Paregoric, other combination 

products 

Oxandrolone (17alpha-methyl-17betahydroxy-2-oxa5alpha-androstan-3-one) 4000 III N Anavar, Lonavar, Oxandrin, 

Provitar, Vasorome 

Oxymesterone (17alpha-methyl-4,17beta

dihydroxyandrost-4-en-3-one) 4000 III N Anamidol, Balnimax, Oranabol, Oranabol 10 

Oxymetholone (17alpha-methyl-2-

hydroxymethylene 17beta-hydroxy5alpha-androstan-3-one)4000 III N Anadrol-50, Adroyd, Anapolon, 

Anasteron, Pardroyd 

Pentobarbital & noncontrolled active 

ingred. 2271 III N FP-3 

Pentobarbital suppository dosage form 2271 III N WANS 
C-10

Table C-3. Schedule III Controlled Substances

SUBSTANCE

DEA 

NUMBER

CSA 

SCH NARC OTHER NAMES

Phendimetrazine 1615 III N Plegine, Prelu-2, Bontril, Melfiat, 

Statobex 

Secobarbital & noncontrolled active 

ingred 2316 III N 

Secobarbital suppository dosage form 2316 III N 

Stanozolol (17alpha-methyl-17betahydroxy-5alpha androst-2-eno[3,2-c]-

pyrazole)

4000 III N Winstrol, Winstrol-V 

Stenbolone (17beta-hydroxy-2-methyl--

5alpha-androst 1-en-3-one) 4000 III N

Stimulant compounds previously excepted 1405 III N Mediatric 

Sulfondiethylmethane 2600 III N 

Sulfonethylmethane 2605 III N 

Sulfonmethane 2610 III N 

Talbutal 2100 III N Lotusate 

Testolactone (13-hydroxy-3-oxo-13,17-

secoandrosta 1,4-dien-17-oic acid lactone) 4000 III N Teolit, Teslac 

Testosterone (17beta-hydroxyandrost-4-

en-3-one) 4000 III N Android-T, Androlan, Depotest, Delatestryl 

Tetrahydrogestrinone (13beta,17alphadiethyl-17beta hydroxygon-4,9,11-trien-3-

one)

4000 III N THG 

Thiamylal 2100 III N Surital 

Thiopental 2100 III N Pentothal 

Tiletamine & Zolazepam Combination 

Product 7295 III N Telazol 

Trenbolone (17beta-hydroxyestr-4,9,11-

trien-3-one) 4000 III N Finaplix-S, Finajet, Parabolan 

Vinbarbital 2100 III N Delvinal, vinbarbitone 

NARC - Narcotic

Table C-4. Schedule IV Controlled Substances

SUBSTANCE

DEA 

NUMBER

CSA 

SCH NARC OTHER NAMES

Alprazolam 2882 IV N Xanax 

Barbital 2145 IV N Veronal, Plexonal, barbitone 

Bromazepam 2748 IV N Lexotan, Lexatin, Lexotanil 

Butorphanol 9720 IV N Stadol, Stadol NS, Torbugesic, 

Torbutrol 

Camazepam 2749 IV N Albego, Limpidon, Paxor 

Cathine 1230 IV N Constituent of "Khat" plant, (+)-

norpseudoephedrine 

Chloral betaine 2460 IV N Beta Chlor 

Chloral hydrate 2465 IV N Noctec 

Chlordiazepoxide 2744 IV N Librium, Libritabs, Limbitrol, SK-Lygen 

Clobazam 2751 IV N Urbadan, Urbanyl 

Clonazepam 2737 IV N Klonopin, Clonopin 

Clorazepate 2768 IV N Tranxene 

Clotiazepam 2752 IV N Trecalmo, Rize, Clozan, Veratran 

Cloxazolam 2753 IV N Akton, Lubalix, Olcadil, Sepazon 
C-11

Table C-4. Schedule IV Controlled Substances

SUBSTANCE

DEA 

NUMBER

CSA 

SCH NARC OTHER NAMES

Delorazepam 2754 IV N 

Dexfenfluramine 1670 IV N Redux 

Dextropropoxyphene dosage 

forms 9278 IV Y Darvon, propoxyphene, Darvocet, Propacet 

Diazepam 2765 IV N Valium, Diastat 

Dichloralphenazone 2467 IV N Midrin, dichloralantipyrine 

Diethylpropion 1610 IV N Tenuate, Tepanil 

Difenoxin 1 mg/25 ug 

AtSO4/du 9167 IV Y Motofen 

Estazolam 2756 IV N ProSom, Domnamid, Eurodin, Nuctalon 

Ethchlorvynol 2540 IV N Placidyl 

Ethinamate 2545 IV N Valmid, Valamin 

Ethyl loflazepate 2758 IV N 

Fencamfamin 1760 IV N Reactivan 

Fenfluramine 1670 IV N Pondimin, Ponderal 

Fenproporex 1575 IV N Gacilin, Solvolip 

Fludiazepam 2759 IV N 

Flunitrazepam 2763 IV N Rohypnol, Narcozep, Darkene, Roipnol 

Flurazepam 2767 IV N Dalmane 

Fospropofol 2138 IV N Lusedra 

Halazepam 2762 IV N Paxipam 

Haloxazolam 2771 IV N 

Ketazolam 2772 IV N Anxon, Loftran, Solatran, Contamex 

Loprazolam 2773 IV N 

Lorazepam 2885 IV N Ativan 

Lormetazepam 2774 IV N Noctamid 

Mazindol 1605 IV N Sanorex, Mazanor 

Mebutamate 2800 IV N Capla 

Medazepam 2836 IV N Nobrium 

Mefenorex 1580 IV N Anorexic, Amexate, Doracil, Pondinil 

Meprobamate 2820 IV N Miltown, Equanil, Micrainin, Equagesic, 

Meprospan 

Methohexital 2264 IV N Brevital 

Methylphenobarbital 

(mephobarbital) 2250 IV N Mebaral, mephobarbital 

Midazolam 2884 IV N Versed 

Modafinil 1680 IV N Provigil 

Nimetazepam 2837 IV N Erimin 

Nitrazepam 2834 IV N Mogadon 

Nordiazepam 2838 IV N Nordazepam, Demadar, Madar 

Oxazepam 2835 IV N Serax, Serenid-D 

Oxazolam 2839 IV N Serenal, Convertal 

Paraldehyde 2585 IV N Paral 

Pemoline 1530 IV N Cylert 

Pentazocine 9709 IV N Talwin, Talwin NX, Talacen, Talwin 

Compound 

Petrichloral 2591 IV N Pentaerythritol chloral, Periclor 

Phenobarbital 2285 IV N Luminal, Donnatal, Bellergal-S 

Phentermine 1640 IV N Ionamin, Fastin, Adipex-P, Obe-Nix, 

Zantryl 

Pinazepam 2883 IV N Domar 
C-12

Table C-4. Schedule IV Controlled Substances

SUBSTANCE

DEA 

NUMBER

CSA 

SCH NARC OTHER NAMES

Pipradrol 1750 IV N Detaril, Stimolag Fortis 

Prazepam 2764 IV N Centrax 

Quazepam 2881 IV N Doral 

Sibutramine 1675 IV N Meridia 

SPA 1635 IV N 1-dimethylamino-1,2-diphenylethane, 

Lefetamine 

Temazepam 2925 IV N Restoril 

Tetrazepam 2886 IV N Myolastan, Musaril 

Triazolam 2887 IV N Halcion 

Zaleplon 2781 IV N Sonata 

Zolpidem 2783 IV N Ambien, Ivadal, Stilnoct, Stilnox 

Zopiclone 2784 IV N Lunesta 

NARC - Narcotic

Table C-5. Schedule V Controlled Substances

SUBSTANCE

DEA 

NUMBER

CSA 

SCH NARC OTHER NAMES

Codeine preparations - 200 mg/100 ml or 100 

gm 

V Y Cosanyl,Robitussin AC,Cheracol,Cerose,Pediacof 

Difenoxin preparations - 0.5 mg/25 ug 

AtSO4/du V Y Motofen 

Dihydrocodeine preparations 10 mg/100 ml or 

100 gm V Y Cophene-S, various others 

Diphenoxylate preparations 2.5 mg/25 ug 

AtSO4 V Y Lomotil, Logen 

Ethylmorphine preparations 100 mg/100 ml or 

100 gm V Y 

Lacosamide 2746 V N Vimpat 

Opium preparations - 100 mg/100 ml or /100 

gm 

V Y Parepectolin, Kapectolin PG, 

Kaolin Pectin P.G. 

Pregabalin 2782 V N Lyrica 

Pyrovalerone 1485 V N Centroton, Thymergix 

NARC - Narcotic